Congestive Heart Failure (Heart Failure) – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Congestive Heart Failure (Heart Failure) – Pipeline Review, H2 2020’, provides an overview of the Congestive Heart Failure (Heart Failure) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure)

– The report reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Congestive Heart Failure (Heart Failure) therapeutics and enlists all their major and minor projects

– The report assesses Congestive Heart Failure (Heart Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4TEEN4 Pharmaceuticals GmbH

Adrenomed AG

AgeX Therapeutics Inc

Amgen Inc

Anchored Rsk3 Inhibitors LLC

Araim Pharmaceuticals Inc

ARCA biopharma Inc

Arena Pharmaceuticals Inc

Armgo Pharma Inc

Ascelegen Therapeutics Inc

Ascendia Pharmaceuticals LLC

Astellas Pharma Inc

AstraZeneca Plc

Athersys Inc

Bayer AG

BEAT BioTherapeutics Corp

Betagenon AB

BioCardia Inc

BlueRock Therapeutics

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

C&C BioPharma LLC

Capricor Therapeutics Inc

Cardiac RSK3 Inhibitors LLC

Cardiol Therapeutics Inc

Cardior Pharmaceuticals GmbH

Cardiora Pty Ltd

CCRP Therapeutics GmbH

Celixir Ltd

CuronBiotech Inc

Cyclerion Therapeutics Inc

Daiichi Sankyo Co Ltd

DepYmed Inc

Elevian Inc

Eli Lilly and Co

Ethicare GmbH

Exscien Corp

F. Hoffmann-La Roche Ltd

G3 Pharmaceuticals Inc

GBSciences Inc

Gmax Biopharm Ltd

Heartseed Inc

Help Therapeutics

Hemostemix Inc

Hunan Jingfeng Pharmaceutical Co Ltd

Hyloris Pharmaceuticals SA

I-Cordis LLC

iHeart Japan Corp

Imbria Pharmaceuticals Inc

Immunwork Inc

Innolife Co Ltd

Innopharmax Inc

Inserm Transfert SA

Intra-Cellular Therapies Inc

INVENT Pharmaceuticals Inc

IsletOne AB

Japan Tobacco Inc

Johnson & Johnson

JT Pharmaceuticals Inc

Juventas Therapeutics Inc

Katakura Industries Co Ltd

KBP BioSciences Co Ltd

Larix Bioscience LLC

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Mesoblast Ltd

Metcela Inc

Mirabilis Therapeutics BV

Miragen Therapeutics Inc

Mitsubishi Tanabe Pharma Corp

Moderna Inc

MyoKardia Inc

Nanjing Transthera Biosciences Co Ltd

NanoCor Therapeutics Inc

NeoProgen Inc

Novartis AG

NovoMedix LLC

Olatec Therapeutics LLC

Orion Corp

Otsuka Holdings Co Ltd

Oxydend Therapeutics Pty Ltd

Palatin Technologies Inc

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

Pharchoice Therapeutics Inc

PhaseBio Pharmaceuticals Inc

Phrixus Pharmaceuticals Inc

Prolifagen LLC

Proveca Ltd

Q BioMed Inc

Quantum Genomics SA

Qurgen Inc

Recardio GmbH

Renova Therapeutics Inc

resTORbio Inc

Ribomic Inc

Rnatives Ltd

Saillant Therapeutics BV

Saje Pharma LLC

Salubris Biotherapeutics Inc

Sanofi

Sarfez Pharmaceuticals Inc

Senju Pharmaceutical Co Ltd

Shanghai Hongyitang Biomedical Technology Co Ltd

Shanghai Life Science & Technology

Shenzhen Salubris Pharmaceuticals Co Ltd

Shin Poong Pharm Co Ltd

Signal Pharma Ltd

Silver Creek Pharmaceuticals Inc

siRNAgen Therapeutics Corp

Sorrento Therapeutics Inc

Stemedica Cell Technologies Inc

Sumocor LLC

Sun Pharma Advanced Research Company Ltd

T&R Biofab Co Ltd

Takeda Pharmaceutical Co Ltd

Tenaya Therapeutics Inc

Toa Eiyo Ltd

Torrent Pharmaceuticals Ltd

TreeFrog Therapeutics SAS

Trio Medicines Ltd

Triple-Gene LLC

U.S. Stem Cell Inc

ViCardia Therapeutics Inc

Viera BioScience Inc

Vifor Pharma Ltd

Viscofan BioEngineering

Windtree Therapeutics Inc

Xcelthera INC

XyloCor Therapeutics Inc

Zensun (Shanghai) Sci & Tech Co Ltd

Table of Contents

Table of Contents

Introduction

Congestive Heart Failure (Heart Failure) - Overview

Congestive Heart Failure (Heart Failure) - Therapeutics Development

Congestive Heart Failure (Heart Failure) - Therapeutics Assessment

Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development

Congestive Heart Failure (Heart Failure) - Drug Profiles

Congestive Heart Failure (Heart Failure) - Dormant Projects

Congestive Heart Failure (Heart Failure) - Discontinued Products

Congestive Heart Failure (Heart Failure) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020 (Contd..1), H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Products under Development by Universities/Institutes, H2 2020 (Contd..1), H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Congestive Heart Failure (Heart Failure) – Pipeline by 4TEEN4 Pharmaceuticals GmbH, H2 2020

Congestive Heart Failure (Heart Failure) – Pipeline by Adrenomed AG, H2 2020

Congestive Heart Failure (Heart Failure) – Pipeline by AgeX Therapeutics Inc, H2 2020

Congestive Heart Failure (Heart Failure) – Pipeline by Amgen Inc, H2 2020

Congestive Heart Failure (Heart Failure) – Pipeline by Anchored Rsk3 Inhibitors LLC, H2 2020

Congestive Heart Failure (Heart Failure) – Dormant Projects, H2 2020

Congestive Heart Failure (Heart Failure) – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports